Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00160342 · ClinicalTrials.gov registry record · Phase 2

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes

A Phase 2 study, sponsored by Solvay Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
1,251
Enrollment target

NCT00160342 is a Phase 2 study that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 1,251 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00160342, a Phase 2 study, has completed, sponsored by Solvay Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
1,251 participants
Enrollment target

Study Summary

This is a research study to evaluate the effectiveness, safety and side effects of several dose levels of esterified estrogens (EE) and methyltestosterone (MT) given individually and in combination compared to a placebo (a tablet with no active drug in it) as a possible treatment for vasomotor symptoms (such as hot flushes and flushing) of menopause. EE and testosterone are two hormones which are typically deficient in menopausal women

Interventions

  • DRUG Esterified Estrogens (EE) and Methyltestosterone (MT)

Trial Details

FieldValue
Enrollment Target 1,251 participants
Start Date 2005-06
Est. Completion 2007-09
Phase Phase 2

Sponsor

Solvay Pharmaceuticals

35 total trials

What the Registry Record Tells You About NCT00160342

The ClinicalTrials.gov registry entry for NCT00160342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Esterified Estrogens (EE) and Methyltestosterone (MT) is the first listed.

NCT00160342 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00160342 about?

NCT00160342 is a clinical study titled "Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes". This is a research study to evaluate the effectiveness, safety and side effects of several dose levels of esterified estrogens (EE) and methyltestosterone (MT) given individually and in combination compared to a placebo (a tablet with no active drug in it) as a possible treatment for vasomotor sympt...

What is the current status of trial NCT00160342?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,251 participants. The study started on 2005-06. Estimated completion is 2007-09.

What interventions are being tested in trial NCT00160342?

The interventions under investigation include: Esterified Estrogens (EE) and Methyltestosterone (MT) (DRUG).

Who is sponsoring clinical trial NCT00160342?

This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.